| Name | Ambrisentan |
| Classes |
Cardiovascular Agent Antihypertensive |
| Diseases |
Pulmonary Atrial Hypertension (PAH) Respiratory Disease |
Bangla
EnglishAmbrisentan
Ambrisentan belongs to the class of drugs known as endothelin receptor antagonists. It selectively blocks endothelin receptors, primarily the endothelin type A (ETA) receptors, leading to vasodilation. This mechanism is beneficial in conditions associated with increased endothelin levels, such as pulmonary arterial hypertension (PAH).
Ambrisentan is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening.
- Adults:
-
- The usual oral dosage is 5 mg once daily.
- Adjustments to 10 mg once daily may be considered based on individual response.
Adverse reactions associated with ambrisentan are listed from most common to least common:
- Peripheral edema
- Headache
- Nasal congestion
- Flushing
- Palpitations
- Anemia
- Abdominal pain
- Fluid retention may require intervention
- If patients develop acute pulmonary edema during initiation of therapy with ambrisentan, consider underlying pulmonary veno-occlusive disease and discontinue treatment if necessary
- Decreases in sperm count have been observed in patients taking endothelin receptor antagonists
- Decreases in hemoglobin have been observed within the first few weeks; measure hemoglobin at initiation, at 1 month, and periodically thereafter
Contraindication
Contraindicated in patients with hypersensitivity to ambrisentan or any of its components.
None known.
